Logo image of IMUX

IMMUNIC INC (IMUX) Stock Overview

NASDAQ:IMUX - US4525EP1011 - Common Stock

0.82 USD
-0.05 (-5.75%)
Last: 8/29/2025, 8:00:02 PM
0.823 USD
+0 (+0.37%)
After Hours: 8/29/2025, 8:00:02 PM

IMUX Key Statistics, Chart & Performance

Key Statistics
52 Week High2.11
52 Week Low0.56
Market Cap80.89M
Shares98.65M
Float97.35M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.94
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/bmo
IPO04-17 2014-04-17
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


IMUX short term performance overview.The bars show the price performance of IMUX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20 -30

IMUX long term performance overview.The bars show the price performance of IMUX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of IMUX is 0.82 USD. In the past month the price decreased by -11.97%. In the past year, price decreased by -45.7%.

IMMUNIC INC / IMUX Daily stock chart

IMUX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About IMUX

Company Profile

IMUX logo image Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 91 full-time employees. The company went IPO on 2014-04-17. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Company Info

IMMUNIC INC

1200 Avenue Of The Americas, Suite 200

New York City NEW YORK 10036 US

CEO: Daniel Vitt

Employees: 90

IMUX Company Website

IMUX Investor Relations

Phone: 13322559818

IMMUNIC INC / IMUX FAQ

What is the stock price of IMMUNIC INC today?

The current stock price of IMUX is 0.82 USD. The price decreased by -5.75% in the last trading session.


What is the ticker symbol for IMMUNIC INC stock?

The exchange symbol of IMMUNIC INC is IMUX and it is listed on the Nasdaq exchange.


On which exchange is IMUX stock listed?

IMUX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for IMMUNIC INC stock?

12 analysts have analysed IMUX and the average price target is 7.96 USD. This implies a price increase of 870.24% is expected in the next year compared to the current price of 0.82. Check the IMMUNIC INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is IMMUNIC INC worth?

IMMUNIC INC (IMUX) has a market capitalization of 80.89M USD. This makes IMUX a Micro Cap stock.


How many employees does IMMUNIC INC have?

IMMUNIC INC (IMUX) currently has 90 employees.


What are the support and resistance levels for IMMUNIC INC (IMUX) stock?

IMMUNIC INC (IMUX) has a support level at 0.81 and a resistance level at 0.9. Check the full technical report for a detailed analysis of IMUX support and resistance levels.


Should I buy IMMUNIC INC (IMUX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does IMMUNIC INC (IMUX) stock pay dividends?

IMUX does not pay a dividend.


When does IMMUNIC INC (IMUX) report earnings?

IMMUNIC INC (IMUX) will report earnings on 2025-11-05, before the market open.


What is the Price/Earnings (PE) ratio of IMMUNIC INC (IMUX)?

IMMUNIC INC (IMUX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).


What is the Short Interest ratio of IMMUNIC INC (IMUX) stock?

The outstanding short interest for IMMUNIC INC (IMUX) is 10.35% of its float. Check the ownership tab for more information on the IMUX short interest.


IMUX Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to IMUX. When comparing the yearly performance of all stocks, IMUX is a bad performer in the overall market: 84.4% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

IMUX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to IMUX. IMUX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IMUX Financial Highlights

Over the last trailing twelve months IMUX reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS increased by 37.33% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -165.78%
ROE -300.3%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%4.76%
Sales Q2Q%N/A
EPS 1Y (TTM)37.33%
Revenue 1Y (TTM)N/A

IMUX Forecast & Estimates

12 analysts have analysed IMUX and the average price target is 7.96 USD. This implies a price increase of 870.24% is expected in the next year compared to the current price of 0.82.


Analysts
Analysts85
Price Target7.96 (870.73%)
EPS Next Y31.92%
Revenue Next YearN/A

IMUX Ownership

Ownership
Inst Owners51.89%
Ins Owners1.31%
Short Float %10.35%
Short Ratio7.01